CALR and heart failure: Notably, the cardiotoxicity detected in the clinical trials that tested the antiangiogenic agent bevacizumab in combination with R-CHOP was severe, being primarily heart failure [23], and was markedly distinct from the asymptomatic elevation of BNP and/or troponin found in the Ro+R-CHOP-treated patients.